• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Assessment of Patient Experiences with Respimat ? in Everyday Clinical Practice
【24h】

Assessment of Patient Experiences with Respimat ? in Everyday Clinical Practice

机译：评估患者经验与RESPIMAT？在日常临床实践中

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionChronic obstructive pulmonary disease (COPD) is a progressive disease requiring maintenance therapy. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report, bronchodilation with long-acting muscarinic antagonists (LAMAs) and long-acting βsub2/sub-agonists (LABAs), administered via inhalers, is currently the mainstay of COPD treatment. Combined LAMA/LABA therapies have been shown to improve patient health status, lung function and breathlessness. Here, we wanted to report patient satisfaction with the Respimatsup?/sup Soft Mist? inhaler (SMI).MethodsThis was a pooled analysis of SPIRITsup?/sup (NCT02675517) and OTIVACTOsup?/sup (NCT02719639), two open-label, single-arm, non-interventional studies of physical function in patients with COPD. Patients were treated with tiotropium/olodaterol 5/5?μg for approximately 6?weeks via the SMI. SPIRIT was conducted in Germany; OTIVACTO was conducted in nine European countries. The primary endpoints have been reported previously. Here, we assess patient satisfaction with inhalation and handling, and patient adherence to treatment with the tiotropium/olodaterol SMI in patients with COPD. These were assessed through self-reported questionnaires and physician general assessments.ResultsBaseline data were collected from 9180 patients from the SPIRIT and OTIVACTO studies. The majority of patients were GOLD group A (25.59%) or B (46.12%). After 6?weeks of treatment with tiotropium/olodaterol, 85.78% of patients were ‘satisfied’ or ‘very satisfied’ with inhaling from the device, and 84.33% of patients were ‘satisfied’ or ‘very satisfied’ with the handling of the inhaler. Treating physicians reported patient adherence as ‘high’ during the study, with 98.57% of patients regularly using the tiotropium/olodaterol SMI. Furthermore, 95.45% of patients expressed a willingness to continue using the tiotropium/olodaterol SMI at the end of the observation period.ConclusionIn this study, over 9000 patients reported satisfaction with respect to inhalation and handling of the Respimat SMI, and patient adherence was high.
机译：引进梗阻性肺疾病（COPD）是一种需要维持治疗的渐进性疾病。根据慢性阻塞性肺病（金）策略报告的全球倡议，通过吸入器给药的长效毒蕈碱拮抗剂（LAMAS）和长效β<亚> 2 软雾？吸入器（SMI）.Methodsthis是对精神的汇总分析？（nct02675517）和otivacto ？（nct02719639），两个开放标签，单臂，非介入研究COPD患者的物理功能。患者通过SMI用噻托溴铵/ olodaterol 5/5μg处理约6.℃。精神在德国进行; Otivacto是在九个欧洲国家进行的。初级终点已经报告过。在这里，我们评估患者对吸入和处理的患者满意度，患者依赖于COPD患者用噻托溴铵/ olodaterol SMI治疗。这些通过自我报告的问卷调查和医生一般性评估进行评估。从9180名来自精神和OTIVACTO研究的患者中收集了条款数据。大多数患者是金组（25.59％）或B（46.12％）。 6次患有Tiotropium / Olodaterol的时间后，85.78％的患者以设备吸入的患者或“非常满意”，84.33％的患者在处理吸入器的情况下“满意”或“非常满意” 。治疗医生报告在研究期间的患者遵守“高”，患者有98.57％的患者经常使用噻托溴铵/ olodaterol SMI。此外，95.45％的患者表示愿意在观察期结束时继续使用噻托溴铵/ olodaterols.Clusualin蛋白，超过9000名患者对吸入和处理Respimat SMI的吸入和处理，并且患者依从性高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号